Researchers shed new light on genetics of Parkinson’s
Fitch Ratings has affirmed Merck & Co.’s (Merck) ratings, and revised the Rating Outlook to Negative from Stable. The ratings affirmed are: Long-term Issuer Default Rating (IDR) at ‘AA-’; Senior unsecured debt rating at ‘AA-’; Bank loan rating at ‘AA-’; Short-term IDR at ‘F1+’. The ratings apply to approximately $6.93 billion of outstanding
Full Post: Fitch Ratings revises Merck & Co.’s outlook
A new study by Narendra et al. suggests that Parkin, the product of the Parkinson’s disease-related gene Park2, prompts neuronal survival by clearing the cell of its damaged mitochondria.
“[This is] an exciting new discovery that links the fields of mitochondrial quality control and the genetics of Parkinson’s disease (PD),” writes Heidi McBride of the University of Ottawa Heart Institute. “?This work significantly increases our understanding of PD and provides a new framework for the development of therapeutic interventions.”
The study, as well as McBride’s commentary, will appear in the December 1, 2008 print issue of the Journal of Cell Biology (JCB). Both articles will be published online Monday, November 24 (www.jcb.org).
Loss-of-function mutations in the gene Park2, which encodes an E3 ubiquitin ligase (Parkin), are implicated in half the cases of recessive familial early-onset Parkinson’s disease. Several lines of evidence suggest that Parkin loss is associated with mitochondrial dysfunction, but exactly how was unknown. To learn more about Parkin’s role in cells, Narendra et al. examined the protein’s subcellular location. They found that Parkin was present in the cytoplasm of most cells, but translocated to mitochondria in cells that had undergone mitochondrial damage such as membrane depolarization.
Damaged mitochondria can trigger cell death pathways; indeed, dysregulation of mitochondrial health was already thought to be a possible cause of the neuronal cell death associated with Parkinson’s disease. The relocation of Parkin to damaged mitochondria, the team showed, sends these defunct organelles to autophagosomes for degradation. Parkin may thus prevent the damaged mitochondria from triggering cell death. Because neurons are not readily replicable, disposing of damaged mitochondria may be especially important in the adult brain.
German scientist Otto H. Warburg’s theory on the origin of cancer earned him the Nobel Prize in 1931, but the biochemical basis for his theory remained elusive. His theory that cancer starts from irreversible injury to cellular respiration eventually fell out of favor amid research pointing to genomic mutations as the cause of uncontrolled cell
Full Post: New evidence in support of Warburg theory of cancer
One of the most reliable indicators to predict that a person will develop type 2 diabetes is the presence of insulin resistance. Insulin is produced in the pancreas and is the hormone responsible for ensuring that glucose reaches several tissues and organs in the body, such as muscles. Insulin resistance is characterized by the lack
Full Post: More data released on key diabetes genes
Maas Biolab researchers CSO Eskil Elmer, M.D., Ph.D. and neuroscientist Magnus Hansson, M.D., Ph.D., and colleagues have for the first time ever demonstrated the mitochondrial permeability transition (mPT) or “megapore” occurs in viable adult human neuron mitochondria and the ability of cyclosporin-A to block its formation. These effects had previously been well characterized in animal
Full Post: Maas Biolab scientists validate cyclosporin human neuroprotection
Neurologists have observed for decades that Lewy bodies, clumps of aggregated proteins inside cells, appear in the brains of patients with Parkinson’s disease and other neurodegenerative diseases. The presence of Lewy bodies suggests underlying problems in protein recycling and waste disposal, leading to the puzzle: how does disrupting those processes kill brain cells? One possible
Full Post: Discovery of potential important pathway for controlling cell loss and survival in Parkinson’s disease
Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson’s disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience. Lorraine Iacovitti, Ph.D., professor and interim director of the Farber Institute for
Full Post: Researchers identify best time for stem cell collection for Parkinson’s therapy